Invicta completes 47% stake sale in Porteus Medical

Invicta Diagnostic Limited has completed the sale of its 47% stake in Porteus Medical LLP. The company executed the third supplementary LLP agreement on May 16, 2026, finalizing the transaction that was initially intimated to the exchanges on January 05, 2026.

The sale consideration amounted to ₹47000. The buyers included Dr. Vishwajeet Arvind Burungale, Dr. Aniruddha Joshi, Dr. Girish Govindrao Kakde, and Dr. Shriganesh Patil, all of whom are radiologists. The company confirmed that none of the buyers belong to the promoter group or group companies.

Financial Details of Subsidiary

According to the disclosures, Porteus Medical LLP reported a turnover of Rs. NIL for the financial year 2024-25. The net worth of the entity as on March 31, 2025, stood at Rs. 1.25 Lakhs, which represented 0.07% of the consolidated net worth of Invicta Diagnostic Limited.

Particulars	Details
Stake Sold	47%
Consideration Received	₹47000
Date of Agreement	May 16, 2026
Date of Completion	May 16, 2026
Turnover FY 2024-25	Rs. NIL
Net Worth (March 31, 2025)	Rs. 1.25 Lakhs

Transaction Compliance

The company stated that the transaction does not fall within related party transactions and was not conducted at arm's length. As the sale constitutes 0.07% of the consolidated net worth of the company, which is less than 20%, the compliance requirements under regulation 37A of the LODR Regulations are not applicable. The disclosures regarding the sale have been uploaded to the company's website.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.72%	-7.05%	-33.61%	-33.39%	-38.00%	-38.00%

Invicta Diagnostic Limited announced the appointment of M/s. Shrenik Nagaonkar & Associates, Company Secretaries, as its Secretarial Auditor, following a resolution passed at the Board of Directors meeting held on May 13, 2026. The appointment covers a term of five financial years, from FY 2025-26 to FY 2029-30, and will be placed before shareholders at the ensuing Annual General Meeting for approval. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board meeting commenced at 7:30 p.m. (IST) and concluded at 8:20 p.m. (IST) on May 13, 2026. The appointment was communicated to the National Stock Exchange of India Limited by Sanket Vinod Jain, Chairman and Non-Executive Director of the company, from Mumbai.

Appointment Details

The key details of the appointment, as disclosed in Annexure I filed with the exchange, are summarised below:

Parameter:	Details
Name:	M/s. Shrenik Nagaonkar & Associates
Designation:	Secretarial Auditor
Date of Appointment:	Wednesday, 13 May, 2026
Term of Appointment:	5 (Five) years — FY 2025-26 to FY 2029-30
Reason for Appointment:	Compliance with Companies Act, 2013 & SEBI (LODR) Regulations, 2015
Equity Shares Held in Company:	NIL
Relationship with Directors:	NIL

Profile of the Secretarial Auditor

Mr. Shrenik Nagaonkar is the proprietor of M/s. Shrenik Nagaonkar & Associates. He brings more than 19 years of experience in corporate governance, encompassing corporate laws, security laws, and capital markets. He is a fellow member of the Institute of Company Secretaries of India and holds a Master of Business Administration with specialisation in Finance. The firm is noted to be a peer-reviewed firm.

Regulatory Compliance

The appointment has been made to comply with the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As required under Regulation 30 of the Listing Regulations, the company has filed the relevant disclosures with the stock exchange. The appointment remains subject to shareholder ratification at the forthcoming Annual General Meeting.